000538 云南白药
2023/09 - 九个月
人民幣(K¥)
与去年同期
比较
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
2019/12
人民幣(K¥)
营业总收入29,688,53210.30%36,488,37336,373,91932,742,76729,664,674
减:营业总成本25,655,34611.08%32,087,16831,739,81828,425,12526,559,856
    其中:营业成本21,561,76711.59%26,883,48526,498,43523,655,87821,191,364
               财务费用(191,246)-9.72%(342,878)(258,281)(231,946)(62,804)
               资产减值损失12,991-102.09%(664,339)(143,220)(125,480)(200,979)
公允价值变动收益103,647-113.79%(619,903)(1,929,217)2,240,369226,836
投资收益703,223-2.31%868,1981,044,401392,1731,470,474
    其中:对联营企业和合营企业的投资收益648,5677.40%732,233(21,100)6,30813,267
营业利润4,873,37792.10%3,371,2793,485,1696,812,0034,742,978
利润总额4,863,76391.73%3,377,0023,481,6466,801,1364,726,189
减:所得税费用741,25786.96%536,593683,9861,290,099553,137
净利润4,122,50692.62%2,840,4102,797,6615,511,0364,173,052
减:非控股权益(971)-99.41%(160,716)(7,256)(5,036)(10,676)
股东净利润4,123,47778.90%3,001,1262,804,9175,516,0724,183,728

市场价值指针
每股收益 (元) *2.31050.98%1.9002.2104.3203.280
每股派息 (元) *----1.5201.6003.9003.000
每股净资产 (元) *22.1985.44%21.42829.80029.78929.699
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容